In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Team

Editorial Team

International

The policy and regulatory insights advantage for biopharma decision-makers around the globe.

Latest From Pink Sheet Team

Pink Sheet Podcast: RWE’s Limited Uses So Far, Learning Pandemic Lessons, COVID-19 Vaccine Reporting Changes

Pink Sheet reporters and editors discuss the role of real world evidence in US FDA product decisions, staffing and other problems that are limiting the agency’s ability to implement lessons from the pandemic, and updates to COVID-19 vaccine adverse event reporting requirements.

Real-World Evidence Coronavirus COVID-19

Pink Sheet Podcast: Amylyx’s Adcom Success, Trials Leave Russia, Apolitical Drug Price Negotiations

Pink Sheet reporters and editors discuss the positive advisory committee recommendation for Amylyx’s proposed ALS treatment, the striking drop in clinical trials conducted in Russia following the start of the war in Ukraine, and questions about Medicare price negotiations avoiding political influence.

Advisory Committees Clinical Trials

Califf Previews US FDA’s Authorization Rationale For COVID Bivalent Boosters

FDA Commissioner says the new shots will skip advisory committee review after June meeting on reformulation. ‘As we know from prior experience, strain changes can be made without affecting safety.’

Coronavirus COVID-19 Vaccines

Pink Sheet Podcast: Trial Diversity, More PTAB Issues, US FDA Controlled Substance Leader Elevated

Pink Sheet reporter and editors discuss another project to improve clinical trial diversity in the US, the Patent Trial and Appeal Board director review process, and the FDA promoting its head of controlled substance policy to deputy CDER director.

Clinical Trials Intellectual Property

Pink Sheet Podcast: Novavax Gets EUA, Califf Sets US FDA Departure, Hemophilia Patients Want REMS

Pink Sheet reporters and editors discuss the FDA’s latest COVID-19 vaccine emergency use authorization, activities during the FDA commissioner’s remaining time in office, and patients requesting a gene therapy risk management plan.

Coronavirus COVID-19 FDA
See All
UsernamePublicRestriction

Register